Angiotensin-converting enzyme (ACE) inhibitors may reduce urinary albumin excretion (UAE) by decreasing glomerular pressure and increasing glomerular charge selectivity through preservation of glycosaminoglycans. The effect of Angiotensin II antagonism on glomerular charge selectivity remains to be determined. The aim of this study was to compare the effects of an AT 1 blocker losartan and an ACE inhibitor (ACE-I) enalapril on UAE, extracellular matrix proteins, glycosaminoglycan excretion (U GAG ) and red blood cell anionic charge (RBCCh) which are the indirect markers of glomerular basement membrane anionic content in hypertensive Type 2 diabetic patients. Twenty-four patients were randomised into two groups and received either enalapril (5-20 mg/d) or losartan (50-100 mg/d). All parameters were measured at baseline and after six months of treatment. At the end of six months, systolic and diastolic blood pressures (BP), UAE rates, U GAG excretion and RBCCh were significantly and equally reduced in both treatment groups compared with baseline. RBCCh was negatively correlated with UAE (r=-0.57, p<0.0001) and U GAG excretion (r=-0.57, p<0.0001); UAE was correlated with U GAG excretion (r=0.58, p<0.0001). In conclusion, enalapril and losartan treatment were equally effective in reducing BP, UAE as well as U GAG excretion and preserving RBCCh in hypertensive Type 2 diabetic patients. ACE inhibition and AT 1 -receptor blockade may have favourable effects on preserving glomerular anionic content in hypertensive diabetic patients.
Introduction
Changes in extracellular matrix components of glomerular basement membrane (GBM) are thought to be involved in the pathogenesis of diabetic nephropathy. 1 Loss of anionic charged proteoglycans may be responsible for the increased excretion of negatively charged albumin. 2 Heparan sulfate proteoglycan is a strong inhibitor of mesangial growth and reduced content of heparan sulfate in GBM was found to be associated with increased Effects of ACE Inhibition and Angiotensin II Receptor Blockade on Glomerular Basement Membrane Protein Excretion and Charge Selectivity in Type 2 Diabetic Patients mesengial expansion in experimental models and also in diabetic patients. 3, 4 The major extracellular matrix protein of the basement membrane, collagen IV, was shown to be increased in the glomerular mesangium and GBM of diabetic patients. 1, 5 Studies which show increased urinary excretion of collagen IV (U CollagenIV ) in proteinuric diabetic patients suggest that urinary measurement of these proteins could reflect matrix changes and GBM damage in patients with diabetes. [6] [7] [8] Angiotensin-converting enzyme (ACE) inhibitors are known to have antiproteinuric effects on the diabetic kidney. 9 Recent studies indicate that the renoprotective effects of ACE inhibitors (ACE-Is) in diabetes could be at least partly independent of their blood pressure (BP)-lowering effects. 10, 11 ACE-Is were shown to preserve anionic content of GBM in experimental diabetic models and limited clinical studies. 12, 13 Other renin-angiotensin system (RAS) inhibitors, Angiotensin II (Ang II) subtype 1 receptor blockers (ARBs) have antihypertensive and antialbuminuric effects comparable to ACE-Is. 9, 14, 15 Although the major mechanism of antialbuminuric action of ARBs was believed to be due to their glomerular arteriolar pressure lowering effects, recent data indicate that renal protective effects of ARBs may also be independent of the reduction in BP. 16 Their effects on glomerular anionic content are currently unknown.
The aim of this study was to evaluate the effects of ACE-Is and ARBs on glomerular charge selectivity, urinary excretion of extracellular matrix proteins such as collagen IV and fibronectin and urinary N-acetylglucoseaminidase (U NAG ) as a tubular marker in hypertensive Type 2 diabetic patients.
Materials and Methods

Patient Selection and Study Design
All male and female patients attending Marmara University Hospital Endocrine and Internal Medicine outpatient clinics with Type 2 diabetes mellitus diagnosed after the age of 30, with mildto-moderate essential hypertension (according to JNC VI), and microalbuminuria, were assessed for All patients were hypertensive for at least six months according to hospital records and none of them were on antihypertensive treatment. There were 28 eligible Type 2 diabetic hypertensive microalbuminuric patients during the randomisation phase of the study. All patients, except two who refused to attend regular visits, were enrolled.
This study was designed as an open-label, parallel-prospective, randomised study, beginning with a six-week titration phase (aiming at a BP target of less than 130/80 mmHg), and a 24week maintenance phase comparing the effects of enalapril and losartan. Data obtained from the control group were only used for cross-sectional comparisons with baseline measurements of hypertensive diabetic groups to clarify the situation about the altered milieu in untreated hypertensive diabetic patients. In addition to home blood glucose monitoring, serum glucose levels and office BPs were measured at monthly intervals and HbA 1C levels every three months. No significant difference in these parameters was observed during the study period. The drug dosages ranged between 5-20 mg/day (Renitec, Merck Sharp Dohme, Turkey) for Enalapril group and 50-100 mg/day (Cozaar, Merck Sharp Dohme, Turkey) for Losartan group.
Lifestyle, diet, oral hypoglycaemic or insulin therapy remained unchanged throughout the study. BP was measured at each visit between 8 and 10 a.m. and 24 hours after medication ingestion, with a standard sphygmomanometer and an appropriately sized cuff. Korotkoff phases I and V were used to determine the systolic and diastolic values, respectively. Three recordings were done in the sitting position after 10 minutes of rest. Patients were randomised into two treatment groups using Arcus QuickStat software. Sequentially numbered opaque, sealed envelopes were prepared according to the list generated by the program and used for the randomisation: 13 patients were given enalapril (Enalapril Group) and 13 were given losartan (Losartan Group). Also 12 age and body mass index (BMI) matched healthy volunteers recruited among hospital staff were included as control group. All control subjects had normal physical findings, a normal electrocardiogram (ECG) and were all free from a family history of hypertension, premature cardiovascular death and diabetes mellitus. Demographic characteristics of the groups are shown in Table 1 . Diabetes was well controlled in all patients, with HbA 1C levels below 7.0% for at least three months before the study. Two patients were on insulin therapy and all others were on oral antidiabetic drugs (OAD).
Compliance and tolerability were assessed by monitoring spontaneous reports of adverse experiences and pill counts at each visit. Twentyfour-hour urine and fasting venous blood samples were collected at the beginning of the study before titration phase and at the end of the study after 24 weeks of the maintenance phase on antihypertensive therapy, and the following parameters were evaluated.
Red Blood Cell Anionic Charge (RBCCh) Measurement
RBCCh was evaluated with a cationic dye (Alcian blue) according to the method of Levin et al. 17 with minor modifications as follows: from citrated venous blood samples, platelets and leukocytes were removed by the method of Beutler et al. 18 RBCs were washed three times in saline, and subsequently a fraction of these cells was 
resuspended in the same solution containing Alcian blue at a final concentration of 250 mg/L. After 30 minutes incubation at 37˚C, the RBC suspension was centrifuged, and the Alcian blue concentration was measured in the supernatant with a Shimatzu UV 2100 spectrophotometer (Shimatzu, Japan) at a wavelength of 650 nm. Each determination represented the mean of two assays. The quantity of Alcian blue bound to RBCs was expressed as nanograms of Alcian blue per 10 6 RBCs. In our experimental conditions the intra-assay and inter-assay coefficients of variation were 5.8 and 7.6%, respectively.
Urinary Glycosaminoglycan Level Determination
Urinary glycosaminoglycan (U GAG ) excretion was determined in 24-hour urine samples spectrophotometrically at 520 nm by the addition of dimethyl-methyleneblue (Aldrich Chem Co., USA) and standard bovine renal heparan sulfate (Sigma, USA). 19 In our experimental conditions the intra-assay and inter-assay coefficients of variation were 2.4 and 1.5%, respectively.
Urinary Albumin Excretion
Urinary albumin excretion was measured with a nephelometric method (BN Prospec, Dade Behring Marburg GmbH). The intra-assay and inter-assay coefficients of variation were 4.3 and 4.4% for a mean value of 45 g/L albumin concentration.
Urinary and Serum IgG Levels
These parameters were also measured nephelometrically by BN Prospec (Dade Behring Marburg GmbH). The intra-assay and inter-assay coefficients of variation were 2.1 and 2.7% for IgG measurements. IgG clearance and IgG/albumin ratio were calculated.
Urinary N-Acetyl-ß-D-Glucosaminidase (NAG) Levels UNAG levels were measured by a colorimetric assay with a kit by Roche Diagnostics GmbH (Mannheim, Germany), the intra and inter-assay coefficients of variation were 4.8% and 5%, respectively.
Urinary Fibronectin
Urinary fibronectin was measured by using ELISA technique. (Takara Shuzo Co. Ltd, Japan). The intra and inter-assay coefficients of variation were 4.7%, and 6%, respectively.
Urinary Collagen IV
Urinary collagen IV was determined by using ELISA Technique (Bio 83).
Statistical Analysis
The analysis of the data was performed with PC compatible Instat-II software. Paired t-test and ANOVA were used where appropriate. Correlation analysis was performed with Pearson test. The differences were considered significant at p<0.05.
The results were given as mean±SD.
Results
There was no significant difference in baseline gender distributions, age, weight, body mass index in control and enalapril or losartan treated diabetic groups. The duration of diabetes and HbA 1C levels were similar in both diabetic groups (see Table 1 ). One patient from the enalapril group had to stop drug treatment because of side effects (cough, dizziness) and one from the losartan group was non-compliant. There were neither deaths nor any cardiovascular events during the course of the study. Twelve patients in each group completed the protocol and were Basal measurements of hypertensive groups were significantly lower than controls (p<0.01) ( Figure 1 ).
Baseline U GAG and U Collagen IV excretions were similar in both diabetic groups but higher than healthy controls (p<0.05). At the end of the six-month treatment period U GAG and U Collagen IV excretions were significantly decreased compared to baseline levels in both treatment groups (p<0.005). A similar trend was observed for U GAG/Cr ratio and U Fibronectin excretion (see Table 2 ). Prior to treatment U NAG levels were significantly higher in diabetic patients than controls (p<0.05). U NAG excretion decreased from 10.4±7 ng/ml at baseline to 4.9±3.3 ng/ml with enalapril treatment (p<0.005) and from 7.7±5.7 ng/ml to 3.3±2.3 ng/ml with losartan treatment (p<0.05). IgG clearance was significantly decreased at the end of the six-month period compared to baseline levels in both enalapril-(p<0.05) and losartan-(p<0.001) treated groups. IgG clearance was not calculated in the control group because seven healthy subjects had undetectable urinary IgG excretion and U GAG excretion. There was no significant difference in any of the followed parameters at the end of the 6 months treatment period between enalapril-and losartan-treated patients (see Table 2 ). UAE was correlated with U GAG ( 
Figure 1
Red blood cell anionic charge measurements before and after treatment in all study groups. Compared with controls pretreatment values were significantly lower in hypertensive Type 2 diabetic patients. After treatment, there was a significant increase in both enalapril (p<0.0001) and losartan (p<0.0005) groups. patients with diabetes evidenced by the Alcian blue binding test agrees well with the loss of the surface of electrical charge and reflects reduced GBM anionic content. 17, [29] [30] [31] Glycosaminoglycans play an important role in GBM permeability. Increased loss of GAG from basement membrane has been postulated to reduce glomerular charge selectivity which contributes to urinary loss of albumin. 12, 33, 34 We found increased U GAG excretion in diabetic patients. Although some studies have shown conflicting results, increased U GAG excretion has been similarly documented in diabetic patients by McAuliffe et al. and De Muro et al. 35, 36 Taken together, these results support the Steno hypothesis which argues that loss of GBM anionic content leads to albuminuria in diabetes. 1 Loss of glycosaminoglycans could be the cause of diminished charge selectivity in diabetic patients. Beneficial effects of ACE-Is and ARBs on charge selectivity could be partly related to decreased loss of GAGs from GBM. Other components of extracellular matrix proteins such as collagen IV and fibronectin are known to be affected by the hyperglycaemic milieu. Increased matrix accumulation in extracellular space and GBM of kidney were reported in diabetes. 1, 5 Increased collagen IV excretion accompanies the overproduction of this extracellular matrix protein in the course of diabetic nephropathy. 7, 8 In this study untreated diabetic patients have higher urinary collagen IV excretion compared with healthy controls and both ACE-Is and ARB treatment decreased urinary collagen IV excretion to a level similar to healthy controls. Baseline urinary fibronectin levels of diabetic patients were found to be increased compared to healthy controls. Although enalapril-treated diabetics had lower levels compared with baseline, the reduction in the losartan-treated group did not reach statistical significance. Reduced collagen IV excretion might indicate inhibition of collagen IV overproduction by ACE-Is or AT 1 -receptor blockers in Type 2 diabetic patients. Although enalapril and losartan have comparable effects in this regard, the effects of enalapril on urinary fibronectin excretion are more pronounced.
In conclusion, ACE-Is and ARBs have comparable effects in preserving GBM anionic content and reducing excretion of collagen IV in Type 2 diabetic patients. Tissue protective effects of RAS inhibition may partly be related to their inhibitory effects on extracellular matrix overproduction and the preservation of anionic charged glycosaminoglycan content of GBM in addition to effective BP control.
Discussion
In this study we observed that treatment with losartan and enalapril for six months reduced UAE significantly and similarly in hypertensive Type 2 diabetic patients. This result is in accordance with previous studies that indicate that ACE-Is and ARBs have similar effects in reducing albuminuria in diabetic patients. 1, 9 As a measure of charge selectivity we evaluated IgG clearance and IgG/albumin ratio. IgG clearance was higher and IgG/albumin ratio was lower in diabetic patients compared with healthy controls. IgG clearance decreased and IgG/albumin ratio increased after treatment with both losartan and enalapril.
In a clinical setting, IgG clearance is one of the proven methods in evaluating GBM charge selectivity. 20 In a recent study, Narita et al. demonstrated an increase in small-sized plasma protein (IgG, IgG4) excretion in normoalbuminuric Type 2 diabetic patients suggesting the role of impaired glomerular pore size selectivity and increased intra-glomerular pressure in the development of diabetic kidney disease. 21 Animal and human studies indicate the favourable effects of ACE-Is on glomerular charge selectivity, 14, 22 but the data about the effects of ARBs on charge selectivity is somewhat unclear. Andersen et al. concluded that AT 1 -receptor blockage repaired the size selective barrier in Type 1 diabetic patients with early diabetic nephropathy. 23 In a Type 1 diabetes animal model, we also found beneficial effects of ACE-Is and neutral effect of ARB on glomerular basement membrane anionic charges while both agents had similar antiproteinuric effects. 24 Hansen et al. 13 have suggested that ACE-Is have favourable effects on glomerular charge selectivity in Type 1 diabetic patients. They found a negative correlation between charge selectivity and urinary albumin excretion. Although captopril treated Type 1 diabetic patients had a higher selectivity index compared with controls, the difference was not statistically significant in their cross-sectional study.
Results of indirect measurements of GBM anionic charge such as RBCCh are in concordance with the results of other studies which show that RBC membrane negative charges are diminished and negatively correlated with the urinary excretion of albumin in patients with diabetes. [25] [26] [27] [28] [29] [30] [31] [32] In our study, RBC anionic charges were significantly increased compared with basal levels in both groups. Negative correlation between RBCCh and UAE is in accordance with the findings of Gambaro et al. who showed abnormal erythrocyte charge in diabetes mellitus was associated with microalbuminuria. 29 RBC membrane anionic charges have been assayed in this study by the binding of the cationic dye Alcian blue which is considered to be a reliable estimation of negative charges on RBC surface. 
Decrease of RBC membrane negative charge in
